VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.3 USD | -0.95% |
|
-3.41% | -3.98% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.56B |
|---|---|---|---|---|---|
| Net income 2024 * | -464M | Net income 2025 * | -509M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-14.2
x | P/E ratio 2025 * |
-13.4
x | Employees | 254 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.09% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxcyte, Inc.
More recommendations
More press releases
More news
| 1 day | -0.95% | ||
| 1 week | -3.41% | ||
| Current month | -11.73% | ||
| 1 month | -10.31% | ||
| 3 months | -4.62% | ||
| 6 months | +25.29% | ||
| Current year | -3.98% |
1 week
59.39
63.22
1 month
59.3969.69
Current year
53.8382.04
1 year
41.5782.04
3 years
15.5182.04
5 years
15.5182.04
10 years
15.5182.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 13-05-26 |
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
| Director of Finance/CFO | 55 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
| Director/Board Member | 58 | 21-09-15 | |
Michael Kamarck
BRD | Director/Board Member | 73 | 21-10-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.27% | 0 M€ | 0.00% | - | |
| 0.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 60.3 | -0.95% | 701,758 |
| 24-04-23 | 60.88 | -1.17% | 665,981 |
| 24-04-22 | 61.6 | +1.27% | 627,167 |
| 24-04-19 | 60.83 | +0.35% | 1,344,223 |
| 24-04-18 | 60.62 | -2.90% | 660,971 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
60.3
USD
Average target price
103.3
USD
Spread / Average Target
+71.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.98% | 6.56B | |
| -1.51% | 104B | |
| +3.22% | 97.42B | |
| +1.86% | 22.2B | |
| -16.53% | 21.23B | |
| -8.49% | 18.33B | |
| -42.33% | 16.35B | |
| -20.09% | 15.06B | |
| +5.47% | 13.98B | |
| +28.85% | 11.66B |
- Stock Market
- Equities
- PCVX Stock
